AVP and Nephropathy: In that study, the risks for ischemic heart disease and cardiovascular mortality were influenced by markers of nephropathy, and the association of copeptin with these outcomes was dependent on UAC, eGFR and on arterial hypertension, mostly a consequence of kidney disease in people with type 1 diabetes.